Green Market Report
Psychedelic clinical research firm Alira Health will collaborate with the Scottsdale Research Institute (SRI) to provide regulatory and clinical support to bring clinical research of psilocybin to the state of Arizona.
Alira said that the partnership would provide strategic guidance and support in regulatory strategy, regulatory submissions, regulatory monitoring, clinical trial design, and clinical operations.
“The state of Arizona is on the cusp of becoming a world leader in conducting first-ever studies of natural psilocybin mushrooms in FDA-controlled trials,” said Dr. Sue Sisley, president of SRI. “Whole psilocybin mushrooms, with all of the molecules working together, could offer superior healing potential than one synthetic molecule, which is the only study drug currently being examined.”
Interested parties in Arizona have been laying the groundwork for psilocybin research. In 2023, a diverse coalition of military veterans, firefighters, and Arizonans with terminal illnesses pushed for the legislature to approve $5 million for natural psilocybin research. According to the statement, this research will be funded through a grant program administered by the Psilocybin Research Advisory Council at the Arizona Department of Health Services.
SRI was awarded the funding to conduct the first controlled study of psilocybin mushrooms in humans, a U.S. Food and Drug Administration Phase 1/2 trial in patients with life-threatening illnesses.
Read full article
